Psyence Biomedical (Psyence Biomedical) Net Margin % : 0.00% (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Psyence Biomedical's Net Income for the six months ended in Mar. 2023 was $-3.10 Mil. Psyence Biomedical's Revenue for the six months ended in Mar. 2023 was $0.00 Mil. Therefore, Psyence Biomedical's net margin for the quarter that ended in Mar. 2023 was 0.00%.

The historical rank and industry rank for Psyence Biomedical's Net Margin % or its related term are showing as below:

PBM's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -154.15
* Ranked among companies with meaningful Net Margin % only.

Psyence Biomedical Net Margin % Historical Data

The historical data trend for Psyence Biomedical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Net Margin % Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Net Margin %

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Net Margin %	-	-	-

Competitive Comparison of Psyence Biomedical's Net Margin %

For the Biotechnology subindustry, Psyence Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Net Margin % falls into.

Psyence Biomedical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Psyence Biomedical's Net Margin for the fiscal year that ended in Mar. 2023 is calculated as

Net Margin	=	Net Income (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-3.097	/	0
	=	%

Psyence Biomedical's Net Margin for the quarter that ended in Mar. 2023 is calculated as

Net Margin	=	Net Income (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-3.097	/	0
	=	%

Psyence Biomedical (NAS:PBM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Psyence Biomedical Net Margin % Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024